Cellular Origins Appoints Geoffrey Hodge as Non-Executive Director
2024年7月11日 - 9:39PM
ビジネスワイヤ(英語)
Appointment brings additional significant
strategic, technical and commercial experience to the Board
Cellular Origins, a TTP Company, focused on enabling scalable,
cost-effective, and efficient manufacture of cell and gene
therapies (CGTs), today announced the appointment of Geoffrey Hodge
to its Board as Non-Executive Director (NED). Leveraging extensive
expertise, knowledge and experience in cell therapy and
biomanufacturing, Geoff’s appointment will strengthen the Company’s
strategic vision and technical capability to deliver accelerated
growth and continued commercial success.
Geoff was most recently CEO of SOTIO Biotech US and CTO of Unum
Therapeutics, both autologous cell therapy companies. Prior to
entering the cell therapy sector, Geoff co-founded Xcellerex, where
he was the primary inventor of the XDR single-use bioreactor and
head of the CDMO biomanufacturing services business, which helped
the company grow to $50M in revenue prior to its acquisition by GE
Healthcare.
In addition to his role on the Board of Cellular Origins, Geoff
will remain part of the Company’s Scientific Advisory Board, where
his extensive experience in developing biomanufacturing technology
and proven commercial success has already helped to shape the
Company’s strategic direction. As NED, Geoff will work closely
alongside the Board and leadership team to accelerate growth and
ensure continued development of the Company’s robotic platform for
cost- and space-efficient manufacture of cell therapies,
Constellation™.
Cellular Origins recently acquired IP to the ACTIA (Autologous
Cell Therapy Industrial Automation) Platform developed by Geoff
whilst he was at SOTIO Biotech1.
Dr Edwin Stone, CEO at Cellular Origins, said: “Geoff has
unique experience having built businesses that have transformed
bioprocess manufacturing. There are very few individuals who have
been through this journey. At Cellular Origins, we know how
important it is to our customers that we can deliver solutions they
can rely on and trust for the manufacturing of important therapies.
Geoff’s expertise in building a business that was successful in
doing this will be invaluable to Cellular Origins. His guidance,
technical and commercial insight and industry network are, and will
continue to be, a crucial asset as we realise our ambition to
achieve faster, cost-effective and efficient routes to scalable
manufacture of cell therapies.”
Geoffrey Hodge, Non-Executive Board Director, Cellular
Origins, commented: “Cellular Origins offers a transformative,
industry-ready solution that addresses the challenges of
manufacturing cell therapies at scale. I look forward to joining
the Board and further deepening my involvement in the Company at
this exciting time in its development and growth.”
1.
https://cellularorigins.com/news/cellular-origins-acquires-actia-platform-ip-to-enhance-automated-cell-therapy-manufacturing/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240711816198/en/
Jake Brown Tel: +44(0) 7759 162147 Email:
jake.brown@zymecommunications.com